An activist shareholder is confronting one of the Bay Area's biggest beneficiaries of the 2017 federal tax overhaul about the company's plans for the windfall.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,